Academic literature on the topic 'Mycosis'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mycosis.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Mycosis"
Sakaniya, L. R., and I. M. Korsunskaya. "Foot mycosis: how to help active patients." Meditsinskiy sovet = Medical Council, no. 12 (October 7, 2020): 24–27. http://dx.doi.org/10.21518/2079-701x-2020-12-24-27.
Full textYakovlev, A. В. "Issues of stage-by-stage approach to the external therapy of foot skin mycosis." Medical Council, no. 21 (January 20, 2019): 146–51. http://dx.doi.org/10.21518/2079-701x-2018-21-146-151.
Full textNakhli, Raja, Mohamed Sbai, Salma Rouhi, Redouane Moutaj, and El Mostafa El Mezouari. "Superficial Mycosis at the Avicenne Military Hospital in Marrakesh: 5-Years Review." Saudi Journal of Medicine 7, no. 1 (January 19, 2022): 52–56. http://dx.doi.org/10.36348/sjm.2022.v07i01.009.
Full textKubanova, A. A., N. V. Kozhichkina, A. A. Kubanova, and N. V. Kozhichkina. "Binafin in treatment of nail mycosis." Vestnik dermatologii i venerologii 86, no. 3 (June 15, 2010): 70–74. http://dx.doi.org/10.25208/vdv850.
Full textThomas, P. A. "Mycotic keratitis — an underestimated mycosis." Medical Mycology 32, no. 4 (January 1994): 235–56. http://dx.doi.org/10.1080/02681219480000321.
Full textAkhmedova, S. D. "Retrospective analysis of the superficial dermatomycosis prevalence in areas of the Greater Caucasus of Azerbaijan." Kazan medical journal 96, no. 6 (December 15, 2015): 1038–42. http://dx.doi.org/10.17750/kmj2015-1038.
Full textReshetnikova, V. P., L. A. Baryshevskaya, O. V. Zeleva, and M. N. Popov. "DIAGNOSTICS OF PHARYNX MYCOSIS." Science and Innovations in Medicine 3, no. 1 (March 15, 2018): 22–25. http://dx.doi.org/10.35693/2500-1388-2018-0-1-22-25.
Full textYamazaki, Toshikazu, Hikaru Kume, Setsuko Murase, Eriko Yamashita, and Mikio Arisawa. "Epidemiology of Visceral Mycoses: Analysis of Data in Annual of the Pathological Autopsy Cases in Japan." Journal of Clinical Microbiology 37, no. 6 (1999): 1732–38. http://dx.doi.org/10.1128/jcm.37.6.1732-1738.1999.
Full textGhitea, Timea Claudia, Simona Bungau, Delia Mirela Tit, Lavinia Purza, Pavel Otrisal, Lotfi Aleya, Gabriela Cioca, Carmen Pantis, and Liviu Lazar. "The Effects of Oregano Oil on Fungal Infections Associated with Metabolic Syndrome." Revista de Chimie 71, no. 1 (February 7, 2020): 335–41. http://dx.doi.org/10.37358/rc.20.1.7854.
Full textVdovina, L. V., N. V. Tiunova, S. M. Tolmacheva, and I. N. Usmanova. "Geotrlchous stomatitis in the dental practice." Endodontics Today 18, no. 2 (August 1, 2020): 68–72. http://dx.doi.org/10.36377/1683-2981-2020-18-2-68-72.
Full textDissertations / Theses on the topic "Mycosis"
Fourel, Didier. "Manifestations viscérales extraganglionnaires du mycosis fongoi͏̈de et de la maladie de Sezary." Bordeaux 2, 1989. http://www.theses.fr/1989BOR25123.
Full textScarisbrick, Julia Jane. "Molecular genetics of mycosis fungoides and Sezary syndrome." Thesis, King's College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.271821.
Full textCOUSTAU, JEAN-YVES. "Traitement du mycosis fongoide : a propos de deux cas cliniques ; revue de la presse internationale." Toulouse 3, 1991. http://www.theses.fr/1991TOU31038.
Full textPERIA, PHILIPPE. "Le mycosis fongoide a plaque unique : a propos de trois observations." Angers, 1994. http://www.theses.fr/1994ANGE1080.
Full textModiano, Philippe. "Association mycosis fongoide et maladie de hodgkin : a propos de deux observations." Nancy 1, 1992. http://www.theses.fr/1992NAN11270.
Full textThaller, Eva. "Untersuchung zur Korrelation von Immunphänotyp und Klonalität bei Mycosis fungoides mittels Lasermikrodissektion." Diss., lmu, 2006. http://nbn-resolving.de/urn:nbn:de:bvb:19-52392.
Full textMarcos, Elaine Valim Camarinha [UNESP]. "Doença de Jorge Lobo e sua relação com os antígenos do sistema HLA." Universidade Estadual Paulista (UNESP), 2001. http://hdl.handle.net/11449/89979.
Full textA doença de Jorge Lobo é uma micose causada pelo fungo Lacazia loboi (L.loboi), o qual se assemelha filogenética e antigenicamente ao Paracoccidioides brasiliensis (P.brasiliensis). Devido às características epidemiológicas e aos poucos estudos relacionados aos aspectos imunológicos dessa doença, o objetivo desse trabalho foi pesquisar a freqüência dos antígenos HLA de classe I e classe II em 21 pacientes portadores da doença de Jorge Lobo e comparar com população controle. As tipagens HLA de classe I foram realizadas pela técnica de microlinfocitotoxicidade e as de classe II pelo método de PCR-SSP. Como controles, utilizaram-se duas populações: uma do Estado do Acre e outra da população brasileira, segundo os dados publicados no 11th IHW no Japão. Esse trabalho sugere a primeira associação proposta entre antígenos e doença de Jorge Lobo, especificamente com o HLA-DQ3, quando comparados os dados entre pacientes e população brasileira. Contudo, não mostra qualquer tipo de associação quando se comparam pacientes e população do Acre. Acredita-se que, com o aumento do número de pacientes estudados e com a utilização de metodologia para identificação dos diferentes alelos que codificam o fenótipo DQ-3, poderão ser obtidos melhores resultados.
Jorge Lobo’s disease is a rare mycosis whose causative agent is the Lacazia loboi (L. loboi), a fungi antigenically and philogenetically similar to the Paracoccidioides brasiliensis (P. brasiliensis). Due to its epidemiological characteristics and the lack of studies related to the immunological aspects of this disease, our objective was to perform HLA class I and II typing in 21 Jorge Lobo’s disease patients and compare their frequency with the healthy population. The Class I HLA typing was done through the lymphotoxicity technique, and the class II HLA determined by the PCR-SSP method. Two control populations were used, one from the state of Acre and the Brazilian population data published at the 11 (IHW) in Japan. Our work suggests the first association proposed between antigen and Jorge Lobo’s disease, specifically the DQ3-HLA, when patients were compared with Brazilian population. However, no association could be demonstrated when patient were compared with the population from Acre. We believe that a larger sample and the use of a method for identification of phenotype DQ-3 encoding allele would give us more detailed results.
Yamashita, Thamy [UNESP]. "Micose fungoide: diagnóstico nas fases iniciais através da correlação clínico-morfológica e imunoistoquímica das lesões." Universidade Estadual Paulista (UNESP), 2011. http://hdl.handle.net/11449/95882.
Full textCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
O diagnóstico preciso das lesões de micose fungoide (MF) em fases iniciais é difícil, pois uma variedade de doenças benignas se sobrepõem clínica e histologicamente. Foram selecionadas 101 biópsias que correspondiam a 67 pacientes cujas lesões se assemelhavam a MF clássica em fases iniciais, do período de 1999 a 2010, que estavam no arquivo do Departamento de Patologia da Faculdade de Medicina de Botucatu - Universidade Estadual Paulista. A proporção entre homens:mulheres foi de 2,6:1, com idades que variaram de 17 a 103 anos e idade média de 62,1 anos. O diagnóstico de MF foi confirmado pela correlação dos aspectos clínicos, histopatológicos e perfil imunoistoquímico. Os pacientes com diagnóstico de MF apresentaram-se com máculas e/ou placas correspondentes aos estágios T1 e T2, geralmente em áreas não expostas ao sol. Desses 67 pacientes analisados, 17 (25,5%) tiveram o diagnóstico de MF caracterizado pelos principais critérios histopatológicos: epidermotropismo desproporcional, microabscessos de Pautrier, alinhamento dos linfócitos e algum grau de atipia linfocitária. Em 3 (4,5%) dos pacientes cujo diagnóstico era MF, não apresentaram todos os principais critérios histopatológicos, porém o diagnóstico foi possível pela correlação com o perfil imunoistoquímico característico de CD3+, CD4+ e redução na expressão de CD8, CD7 e/ ou CD2 e CD5. Em 15 (22,5%) casos a suspeita para MF manteve-se, e, em 32 (47,5%) pacientes o diagnóstico de MF foi excluído e esses casos foram classificados como outras doenças. Portanto, mais de 47% dos pacientes foram falso-positivos se considerarmos apenas os aspectos clínicos. Embora o estudo imunoistoquímico seja uma importante técnica diagnóstica auxiliar, a maioria dos diagnósticos das lesões iniciais de MF dependem principalmente da correlação do histórico clínico e achados histopatológicos
Accurate diagnosis of early lesions of mycosis fungoides (MF) is difficult because of the varied clinical and histological patterns that may mimic other benign conditions. Data from 101 biopsies from 67 patients with lesions that seemed classical early MF registered between 1999 and 2010 were retrieved from the Department of Pathology at Botucatu Medical School - Sao Paulo State University. The male:female ratio = 2.6:1, age range17-103 years and mean age, 62.1 years. The diagnosis of MF was confirmed by correlation with clinical features, histopathology and immunohistochemistry technique. All MF patients presented patch and/or plaques corresponding the T1 and T2 disease staging, usually in non-exposed areas. Out of 67 patients analysed, 17 (25,5%) had the diagnosis of early MF histopathologically characterized by the main diagnostic criteria which are disproportionate epidermotropism, Pautrier’s microabscesses, linear arrangement distribution of lymphocytes and some degree of lymphocyte atypia. In 3 (4,5%) patients the diagnosis of MF did not have all the main histopathological criteria, but was also supported by CD3+, CD4+ and reduction of expression of CD8, CD7 and/ or CD2 and CD5, 15 (22,5%) cases remain suspicious for MF and 32 (47,5%) patients were ruled out as other diseases. Indeed, more than 47% were false positive for MF considering only the clinical aspects. Although immunohistochemistry may help, the majority of the diagnosis of early MF still rests upon clinical features and histopathological findings
Marcos, Elaine Valim Camarinha. "Doença de Jorge Lobo e sua relação com os antígenos do sistema HLA /." Botucatu : [s.n.], 2001. http://hdl.handle.net/11449/89979.
Full textResumo: A doença de Jorge Lobo é uma micose causada pelo fungo Lacazia loboi (L.loboi), o qual se assemelha filogenética e antigenicamente ao Paracoccidioides brasiliensis (P.brasiliensis). Devido às características epidemiológicas e aos poucos estudos relacionados aos aspectos imunológicos dessa doença, o objetivo desse trabalho foi pesquisar a freqüência dos antígenos HLA de classe I e classe II em 21 pacientes portadores da doença de Jorge Lobo e comparar com população controle. As tipagens HLA de classe I foram realizadas pela técnica de microlinfocitotoxicidade e as de classe II pelo método de PCR-SSP. Como controles, utilizaram-se duas populações: uma do Estado do Acre e outra da população brasileira, segundo os dados publicados no 11th IHW no Japão. Esse trabalho sugere a primeira associação proposta entre antígenos e doença de Jorge Lobo, especificamente com o HLA-DQ3, quando comparados os dados entre pacientes e população brasileira. Contudo, não mostra qualquer tipo de associação quando se comparam pacientes e população do Acre. Acredita-se que, com o aumento do número de pacientes estudados e com a utilização de metodologia para identificação dos diferentes alelos que codificam o fenótipo DQ-3, poderão ser obtidos melhores resultados.
Abstract: Jorge Lobo's disease is a rare mycosis whose causative agent is the Lacazia loboi (L. loboi), a fungi antigenically and philogenetically similar to the Paracoccidioides brasiliensis (P. brasiliensis). Due to its epidemiological characteristics and the lack of studies related to the immunological aspects of this disease, our objective was to perform HLA class I and II typing in 21 Jorge Lobo's disease patients and compare their frequency with the healthy population. The Class I HLA typing was done through the lymphotoxicity technique, and the class II HLA determined by the PCR-SSP method. Two control populations were used, one from the state of Acre and the Brazilian population data published at the 11 (IHW) in Japan. Our work suggests the first association proposed between antigen and Jorge Lobo's disease, specifically the DQ3-HLA, when patients were compared with Brazilian population. However, no association could be demonstrated when patient were compared with the population from Acre. We believe that a larger sample and the use of a method for identification of phenotype DQ-3 encoding allele would give us more detailed results.
Mestre
Carvalho, Fabiana Moura de. "Avaliação da associação sulfametoxazol-trimetropim no tratamento da paracoccidioidomicose experimental murina /." Botucatu : [s.n.], 2006. http://hdl.handle.net/11449/106361.
Full textBanca: Eva Burger
Banca: Roberto Martinez
Resumo: O tratamento da PCM, micose sistêmica causada Paracoccidioides brasiliensis, continua sendo objeto de pesquisa clínica e experimental. Este trabalho avaliou a eficácia de diferentes esquemas terapêuticos com cotrimoxazol (CMX), na dose diária de 200 mg/kg de peso corporal, em dose diária única, no tratamento da PCM murina. Os resultados revelaram que o tratamento com CMX por tempo prolongado foi eficaz quando iniciado precoce ou tardiamente. O tratamento com curta duração foi ineficaz, pois não determinou diminuição da carga fúngica, durante as 20 semanas de seguimento. O efeito do CMX foi o mesmo em pulmões e baço, nos diferentes esquemas terapêuticos utilizados, eficazes ou não. A mortalidade cumulativa entre os grupos 1, 2 e 4 não diferiram entre si, os grupos 3 e 5 apresentaram a melhor taxa de sobrevida. Os níveis séricos de anticorpos específicos foram detectados a partir da segunda semana, apresentando maiores índices nos animais do G2, sendo que nesses os níveis aumentaram até a oitava semana e permanecendo estáveis por todo o experimento. No G3 houve uma flutuação durante todo o experimento apresentando níveis altos na 20a semana. Os grupos 4 e 5 permaneceram estáveis durante todo o experimento. Os efeitos benéficos do tratamento foram observados com a administração de CMX em dose única diária, cujos níveis séricos se mantiveram adequados por menos de 12 horas. Esses resultados, bastante satisfatórios, demonstram que o modelo experimental murino é bom método de avaliação da eficácia do CMX no tratamento da PCM e sugerem a avaliação de outros esquemas terapêuticos, como a administração a cada 12 horas.
Abstract: Paracoccidioidomicosis (PCM) treatment, a systemic mycosis caused by Paracoccidioides brasiliensis, has been a clinical and experimental research issue. This work evaluated the efficacy of different therapeutic protocols with cotrimoxazole (CMX) on a daily dosage of 200mg/kg body weight, in a single daily dosage on murine PCM treatment. The results showed that CMX treatment for a prolonged period was efficient when started early or late. The short duration treatment was inefficient once it did not determine fungus load decrease during 20 weeks of following. CMX effect was the same in lungs and spleen under different therapeutic protocols used, whether efficient or not. Cumulative death tends to be different among studied groups. Death frequency was smaller in prolonged treated groups with an early or late protocol starting. Specific antibodies blood levels were detected from the second week and did not differ among experimental groups. Beneficial effects of treatment were observed with CMX administration on a daily single dosage and blood levels remained satisfactory for less than 12 hours. These results, quite satisfactory, show that murine experimental protocol is a good evaluation method of MCX effectiveness on PCM treatment and it suggests the evaluation of other therapeutic protocols, as an administration at every 12 hours.
Doutor
Books on the topic "Mycosis"
Khan Mohammad Beigi, Pooya. Clinician's Guide to Mycosis Fungoides. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47907-1.
Full textS, Zackheim Herschel, ed. Cutaneous T-cell lymphoma: Mycosis fungoides and Sézary syndrome. Boca Raton, Fla: CRC Press, 2005.
Find full textPresterl, Elisabeth, ed. Clinically Relevant Mycoses. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-92300-0.
Full textSymposium on Topics in Mycology on Mycoses in AIDS Patients (1989 Paris, France). Mycoses in AIDS patients. New York: Plenum Press, 1990.
Find full textG, Braun Dietmar, and Koch Herbert A, eds. An atlas of mycoses. Berlin: Grosse, 1988.
Find full textCutsem, J. Van. Mycoses in domestic animals. Beerse, Belgium: Janssen Research Foundation, 1991.
Find full textBossche, Hugo Vanden, Donald W. R. Mackenzie, Geert Cauwenbergh, Jan Van Cutsem, Edouard Drouhet, and Bertrand Dupont, eds. Mycoses in AIDS Patients. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0655-9.
Full text1964-, Lang Heidi, and Parish Lawrence Charles, eds. Manual of medical mycology. Cambridge, Mass., USA: Blackwell Scientific, 1995.
Find full textTan, C. Shu-hui. Fungi that cause superficial mycoses. Baarn: Centraalbureau voor Schimmelcultures, 1994.
Find full textBook chapters on the topic "Mycosis"
Nolting, Siegfried, and Klaus Fegeler. "Diseases Resembling Mycosis — Saphrophytic Mycoses." In Medical Mycology, 121–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72553-1_6.
Full textMehlhorn, Heinz. "Mycosis." In Encyclopedia of Parasitology, 1718. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-43978-4_4081.
Full textMehlhorn, Heinz. "Mycosis." In Encyclopedia of Parasitology, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27769-6_4081-1.
Full textHangay, George, Susan V. Gruner, F. W. Howard, John L. Capinera, Eugene J. Gerberg, Susan E. Halbert, John B. Heppner, et al. "Mycosis." In Encyclopedia of Entomology, 2517. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6359-6_4747.
Full textGooch, Jan W. "Mycosis." In Encyclopedic Dictionary of Polymers, 909. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_14282.
Full textBensard, Denis D., Philip F. Stahel, Jorge Cerdá, Babak Sarani, Sajid Shahul, Daniel Talmor, Peter M. Hammer, et al. "Mycosis, Opportunistic." In Encyclopedia of Intensive Care Medicine, 1486–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_43.
Full textBensard, Denis D., Philip F. Stahel, Jorge Cerdá, Babak Sarani, Sajid Shahul, Daniel Talmor, Peter M. Hammer, et al. "Mycosis, Endemic." In Encyclopedia of Intensive Care Medicine, 1486. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_44.
Full textLlewellyn, Moses. "Mycosis Fungoides." In When Doctors Get Sick, 321–24. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4899-2001-0_35.
Full textMaibach, Howard. "Skin Mycosis." In Drug Discovery and Evaluation: Pharmacological Assays, 3955–59. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-05392-9_105.
Full textPatel, Nisha R., Michael L. Wong, Anthony E. Dragun, Stephan Mose, Bernadine R. Donahue, Jay S. Cooper, Filip T. Troicki, et al. "Mycosis Fungoides." In Encyclopedia of Radiation Oncology, 521. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_475.
Full textConference papers on the topic "Mycosis"
Hanaoka, K., Y. Onishi, R. Kagami, R. Katsuda, K. Miyake, Y. Mizumori, H. Tsukamoto, S. Sasaki, T. Kawamura, and Y. Nakahara. "Real World Practice for Allergic Bronchopulmonary Mycosis (ABPM)." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2967.
Full textLéger, C., E. Delandre, A. Durand, A. Chaupin-Prieur, and L. Caumette. "4CPS-032 Skin protection and prevention of cutaneous mycosis." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.181.
Full textЛарина, Г. Е., Л. Г. Серая, С. А. Голимбовская, Т. А. Петровнина, И. Н. Калембет, Н. Н. Полякова, Н. Ю. Гудкова, and О. А. Быкова. "PHYTOPATHOLOGY (MYCOSIS) OF MEDICINAL PLANTS IN PERMANENT COLLECTION PLANTS." In 90 лет - от растения до лекарственного препарата: достижения и перспективы. Москва: Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт лекарственных и ароматических растений", 2021. http://dx.doi.org/10.52101/9785870191003_2021_83.
Full textAisyah, P., F. F. Taufik, M. Elhidsi, and J. Zaini. "Coincidence of Lung Mycosis and Tuberculosis in Squamous Cell Carcinoma." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4543.
Full textSygaieva, Iryna. "Mycosis induced asthma treatment: fluticasone/salmeterol vs. budesonide/formoterol reinforced by montelukast." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4024.
Full textMohan, A., H. Iyer, `. Madan, V. Hadda, R. Guleria, S. Mittal, P. Tiwari, and A. S. Bhalla. "Isolated Mediastinal Aspergillosis in an Immunocompetent Female: A Rare Cause of Pulmonary Mycosis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3972.
Full textWang, Kevin Y., Tao Wang, Yuehua Liu, and Christine Lian. "Abstract 220: Disease monitoring of mycosis fungoides via high throughput sequencing of CDR3." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-220.
Full textRendon-Serna, Natalia, Maeva Dufies, Luis Alfonso Correa-Londono, Olga Maria Bermudez-Munoz, Margarita Maria Velasquez-Lopera, and Gilles Pages. "Abstract 2650: Angiogenic inhibitors reduce mycosis fungoides cell survival and enhance cell death." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2650.
Full textBenzrath, Stefanie, Anne Schlegtendal, Folke Brinkmann, and Cordula Koerner-Rettberg. "Allergic bronchopulmonary mycosis due to rhizopus nigricans in two siblings with and without CF?" In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1247.
Full textChen, Gwo-Hsiao, John J. Osterholzer, Michal A. Olszewski, Roderick A. McDonald, Mun Choe, Gary B. Huffnagle, and Galen B. Toews. "INTERPLAY OF CD40-DEPENDENT AND INDEPENDENT MECHANISMS IN THE PATHOGENESIS OF MURINE ALLERGIC BRONCHOPULMONARY MYCOSIS." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1808.
Full textReports on the topic "Mycosis"
Mateeva, Valeria, Doncho Etugov, and Grisha Mateev. Efficacy of Systemic PUVA (Psoralen Plus Ultraviolet Light-A) in Bulgarian Patients with Mycosis Fungoides. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, November 2018. http://dx.doi.org/10.7546/crabs.2018.11.15.
Full text